Onartuzumab, a humanized monoclonal anti-MET antibody, inhibited glioblastoma growth in a preclinical testing [84]; however, the combination treatment of onartuzumab with bevacizumab showed no clinical benefit compared to that with bevacizumab plus placebo [85]. The gene discussed is MET; the disease is glioblastoma.